AAM Opposes Oregon’s SB 764 Settlements Bill
Association Says ‘Unnecessary’ Legislation Will Delay Access And Drive Up Prices
Executive Summary
Proposed state legislation restricting patent settlements set out in Oregon’s SB 764 bill is “unnecessary,” the AAM has insisted, opposing the “unconstitutional” legislation by citing delayed patient access to affordable medicines, the obstruction of expedited patent settlements and benefits to brand-name pharmaceutical companies which will eventually lead to price rises.
You may also be interested in...
AAM Succeeds As California Court Temporarily Blocks Pay-For-Delay Law
A judge in California has agreed to instate a temporary injunction against a state law designed to curb so-called ‘pay-for-delay’ deals, handing victory to generics and biosimilars industry association the AAM.
AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics
The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.